Chronic lowering of blood pressure by carotid baroreflex activation: Mechanisms and potential for hypertension therapy

Hypertension

Volumn 57, Issue 5, 2011, Pages 880-886

  Lohmeier, Thomas E ^a   Iliescu, Radu ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; PRAZOSIN; PROPRANOLOL;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CAROTID SINUS PRESSORECEPTOR REFLEX; CHRONIC BLOOD PRESSURE LOWERING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; ELECTROSTIMULATION; HEALTH CARE COST; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY; MEDICAL INSTRUMENTATION; NATRIURESIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RESISTANT HYPERTENSION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SAFETY; SODIUM INTAKE; SYMPATHETIC TONE; THERAPY EFFECT; WATER RETENTION;

BAROREFLEX; BLOOD PRESSURE; CAROTID SINUS; HUMANS; HYPERTENSION; KIDNEY; PRESSORECEPTORS;

EID: 79955473943     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.119859     Document Type: Article

References (39)

1. Schwartz SI, Griffith LSC, Neistadt A, Hagfors N. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg. 1967;114:5-15.
2. Tuckman J, Reich T, Lyon AF, Goodman B, Mendlowitz M, Jacobson JH. Electrical stimulation of the sinus nerves in hypertensive patients: clinical evaluation and physiological studies. In: Wood JE, ed. Hypertension 16: Neural Control of Arterial Pressure. New York, NY: American Heart Association; 1968:23-26.
3. Lohmeier TE, Barrett AM, Irwin ED. Prolonged activation of the baro-reflex: a viable approach for the treatment of resistant hypertension? Curr Hypertens Rev. 2005;7:193-198. (Pubitemid 40894925)
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252. (Pubitemid 37553153)
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica A, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;117:e510-e526.
6. Lohmeier TE, Irwin ED, Rossing MA, Sedar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306-311. (Pubitemid 38174130)
7. Cowley AW Jr. Long-term control of arterial pressure. Physiol Rev. 1992;72:231-300.
8. Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regulatory Integrative Comp Physiol. 2005;288:R828-R836. (Pubitemid 40404155)
9. Lohmeier TE, Drummond HA. The baroreflex in the pathogenesis of hypertension. In: Lip GYH, Hall JE, ed. Comprehensive Hypertension. Philadelphia, PA: Elsevier; 2007:265-279.
10. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular diseases. Physiol Rev. 2010;90:513-557.
11. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Sedar DJ, Kieval RS. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46: 1194-1200. (Pubitemid 41533025)
12. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, Kieval RS. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007; 49:373-379. (Pubitemid 46143015)
13. Lohmeier TE, Dwyer TM, Irwin ED, Rossing MA, Kieval RS. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307-1314. (Pubitemid 46809373)
14. Lohmeier TE, Hildebrandt DA, Dwyer TM, Iliescu R, Irwin ED, Cates AW, Rossing MA. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension. 2009;53:833-838.
15. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010;299:H402-H409.
16. Charkoudian N, Joyner MJ, Sokolnicki LA, Johnson CP, Eisenach JH, Dietx NM, Curry TB, Wallin BG. Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. J Physiol. 2006;572:821-827.
17. Guyton AC Arterial Pressure and Hypertension. Philadelphia, PA: Saun-ders; 1980.
18. Carroll RG, Lohmeier TE, Brown AJ. Chronic angiotensin II infusion decreases renal norepinephrine overflow in the conscious dog. Hypertension. 1984;6:675-681. (Pubitemid 15210509)
19. Lohmeier TE, Lohmeier JR, Haque A, Hildebrandt DA. Baroreflexes prevent neurally-induced sodium retention in angiotensin hypertension. Am J Physiol Regulatory Integrative Comp Physiol. 2000;279: R1437-R1448.
20. Barrett CJ, Guild S-J, Ramchandra R, Malpas SC. Baroreceptor dener-vation prevents sympathoinhibition during angiotensin II-induced Hypertension. Hypertension. 2005;46:1-5.
21. Iliescu R, Lohmeier TE. Lowering of blood pressure during chronic suppression of central sympathetic outflow: insight from computer sim-ulations. Clin Exp Pharmacol Physiol. 2009;37:e24-e33.
22. Kirchheim HR, Finke R, Hackenthal E, Lowe W, Persson P. Baroreflex sympathetic activation increases threshold pressure for pressure-dependent renin release. Pfleugers Arch. 1985;405:127-135. (Pubitemid 16255601)
23. Yang HM, Lohmeier TE, Kivlighn SD, Smith MJ Jr. Sustained increases in plasma epinephrine concentration do not modulate renin release. Am J Physiol Endocrinol Metab. 1989;257:E57-E64.
24. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14:103s-115s. (Pubitemid 32506704)
25. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48:1-10.
26. Shibao C, Gamboa A, Diedrich A, Ertl AC, Chen KY, Byrne DW, Farley G, Paranjape SY, Davis SN, Biaggioni I. Hypertension. 2007;49:17-33.
27. Fu Q, Zhang R, Witkowski S, Arbab-Zadeh A, Prasad A, Okazaki K, Levine BD. Persistent sympathetic activation during chronic antihyper-tensive therapy: a potential mechanism for long-term morbidity? Hypertension. 2005;45:513-521. (Pubitemid 40411252)
28. De Champlain J, Karas M, Nguyen P, Cartier P, Wistaff R, Toal CB, Nadeau R, Larochelle P. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens. 1998;16:1357-1369. (Pubitemid 28408419)
29. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IHH, Dijkhorst-Oei L-T, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328. (Pubitemid 29196594)
30. Lohmeier TE, Hildebrandt DA, Hood WA. Renal nerves promote sodium excretion during long-term increases in salt intake. Hypertension. 1999; 33:487-492. (Pubitemid 29065708)
31. Buckwalter JB, Clifford PS. α-Adrenergic vasoconstriction in active skeletal muscles during dynamic exercise. Am J Physiol Heart Circ Physiol. 1999;277:H33-H39. (Pubitemid 29354675)
32. Dinenno FA, Eisenach JH, Dietz NM, Joyner MJ. Post-junctional α-adrenoceptors and basal limb vascular tone in healthy men. J Physiol. 2002;540:1103-1110. (Pubitemid 35190179)
33. Iliescu R, Dwyer TM, Irwin ED, Georgakopoulos D, Rossing MA, Lohmeier TE. Electrical activation of carotid baroreflex enhances the chronic blood pressure lowering effects of calcium channel blockade by abolishing sympathoexcitation [abstract]. Hypertension. 2010;56: e71-e72.
34. Scheffers IJM, Kroon AA, Schmidli J, Jordan J, Tordoir JJM, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension. J Am Coll Cardiol. 2010;56: 1254-1258.
35. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FCGJ, Haller H, Pichlmaier, LuftF, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-626.
36. Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, Schmidli J, Allemann Y, Delacretaz E. Effects of chronic barore-ceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54: 530-536.
37. Parati G. Blood pressure variability: its measurement and significance. J Hypertens. 2005;23:s19-s25.
38. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M, for the Symplicity HTN-2 investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-1909.
39. Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, Irwin ED, Serdar DJ, Peuler JD, Rossing RA. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension. 2007;50:904-910. (Pubitemid 350287533)